Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study to Evaluate the Safety and Preliminary Efficacy of ATA3219, Allogeneic Anti-CD19 Chimeric Antigen Receptor T-cell Therapy, in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Next Previous
Search
Trial Profile

A Phase 1 Study to Evaluate the Safety and Preliminary Efficacy of ATA3219, Allogeneic Anti-CD19 Chimeric Antigen Receptor T-cell Therapy, in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 29 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ATA 3219 (Primary)
  • Indications B-cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Atara Biotherapeutics

Most Recent Events

  • 24 Apr 2025 Status changed from suspended to discontinued.
  • 07 Mar 2025 According to Atara Biotherapeutics media release, First patient successfully completed dosing in the Phase I dose escalation study, evaluating the safety and efficacy of ATA3219
  • 21 Jan 2025 According to Atara Biotherapeutics media release, the company announced that the U.S. Food FDA has placed a clinical hold on company's Investigational New Drug (IND) application. Screening and enrollment of new participants have been paused and specifically identified subjects currently enrolled in the study who have the potential to derive clinical benefit may continue to receive treatment in accordance with the study protocol.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top